Oral tyrosine kinase inhibitor tablets at 300 mg strength for medullary thyroid carcinoma management. Pharmaceutical wholesalers distribute to endocrinology and oncology units in medical facilities. Procurement focuses on targeted therapy supplies for specialized cancer care.